18 years and older
Male or Female
Patients undergoing treatment with durvalumab for unresectable Stage III non-small cell lung cancer (NSCLC) after 2 or more cycles of concurrent platinum-based chemotherapy and radiation therapy can experience pulmonary adverse events (AEs) that lead to treatment discontinuation and morbidity. This study, ON TRAX, is a pilot study to evaluate the potential benefit of multiparametric mobile applications and connected medical devices in collecting data to facilitate or improve early identification of pulmonary AEs in patients with unresectable Stage III NSCLC receiving durvalumab treatment. The outcomes of this study will determine whether this multiparametric mobile technology will be progressed to a fully powered study for the early detection of pneumonitis and pulmonary AEs in patients with unresectable Stage III NSCLC. This project seeks to understand if the multiparametric mobile technology devices integrate well into a patient’s daily life with minimal burden and to collect vital signs and respiratory data. These devices can then track and detect changes in a patient’s vital signs and respiratory function and aid physicians in detection of pulmonary AEs.
For further information about this study or to express your interest in this study, please fill out and submit this form.
This setting allows you to view available services and providers associated with your preferred location. You can change this setting at any time.
Cookies are required to view location specific content.
We’ve developed a new tool on our website allowing you to see content most relevant to you and your preferred location. It’s our way of making the information you need, more personalized.
You’ll find this feature labeled “Set My Location” throughout the website. Most often, you’ll see it in the top left corner of every page.
You’ll also find a feature that allows you to set your location temporarily, as seen below.